Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1Other 1

Conditions

Mesothelioma 58Advanced Solid Tumors 52Mesothelioma, Malignant 51Solid Tumors 43Solid Tumor 35Advanced Solid Tumor 23Carcinoma, Non-Small-Cell Lung 20Lung Neoplasms 12Ovarian Neoplasms 10Melanoma 10Esophageal Neoplasms 10Stomach Neoplasms 9Small Cell Lung Carcinoma 9Retinoblastoma 9Carcinoma, Renal Cell 9Unspecified Adult Solid Tumor, Protocol Specific 8Solitary Fibrous Tumor, Pleural 8Sarcoma 8Pancreatic Neoplasms 8Neoplasm Metastasis 8Breast Neoplasms 7Uterine Cervical Neoplasms 6Malignant Solid Tumor 6Triple Negative Breast Neoplasms 5Squamous Cell Carcinoma of Head and Neck 5Solid Tumor, Adult 5Osteosarcoma 5Metastatic Solid Tumors 5Liver Neoplasms 5Colorectal Neoplasms 5

Interventions

Cannabidiol 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Chemotherapy-Induced Peripheral Neuropathy × Other solid neoplasm × Clear all
NCT05388058 2026-01-16

Topical Cannabidiol for the Treatment of Chemotherapy-Induced Peripheral Neuropathy

Mayo Clinic

Phase 2 Completed
40 enrolled 15 charts
OtherOther solid neoplasm

Chemotherapy-Induced Peripheral Neuropathy

Data powered by HemOnc (CC BY 4.0) Colophon âš¡